Two Pharma Giants Fall into the 'Deepest Pitfall' of Innovative Drug Development: Novo Nordisk and Johnson & Johnson Report Failures in Alzheimer’s Trials
Johnson & Johnson
Medical Device R&D and Manufacturer
In the last week of November 2025, the global innovative drug industry witnessed two clinical development failures.
Within just four days, Novo Nordisk, the global metabolic drug giant, and Johnson & Johnson, a long-established multinational pharmaceutical company, have both encountered setbacks in their pivotal Phase III and Phase II clinical trials for Alzheimer's disease (AD), respectively.
As a high-difficulty indication that has continuously knocked down many multinational pharmaceutical companies in recent years, Alzheimer's disease once again demonstrates the terrifying nature of the "innovative drug quagmire."
First up is Novo Nordisk, a company banking on its top ace, also one of the hottest blockbuster drugs globally in recent years: Semaglutide.
On November 24, Novo Nordisk announced that its oral version of semaglutide showed results in two pivotal Phase III clinical trials (EVOKE and EVOKE+) for the treatment of early Alzheimer's disease.The primary clinical endpoint did not demonstrate a statistically significant treatment advantage compared to placebo.
In view of the above results,Novo Nordisk's stock price plummeted on the same day, and the company has also decided to halt the subsequent extension studies of these two trials.
Previously, there was a widespread speculation in the industry that GLP-1 drugs could treat Alzheimer's disease by reducing inflammation and improving metabolism. There was even a hypothesis that Alzheimer's disease is "Type III diabetes."
This clinical trial failure of Novo Nordisk is a ruthless and complete rejection of the above speculation.
Novo Nordisk's failed attempt in Alzheimer's disease this time fully reflects one major characteristic of this indication:The research community knows almost nothing about its pathogenesis, and the development strategy is basically dependent on various assumptions, conjectures, and incidental observations.。
In November 2020, Novo Nordisk released a post-hoc pooled analysis of semaglutide in three clinical studies targeting cardiovascular indications, which showed:The risk of dementia in the GLP-1 treatment group was 53% lower than in the placebo group.
Specifically,A total of 15,820 patients were followed up for an average of 3.6 years. In the placebo group, 32 patients developed Alzheimer's disease, while in the GLP-1 drug treatment group, only 15 patients did.
Although the number of cases is not large, the figure of "53% reduction" is so impressive that Novo Nordisk believes it holds not only the "Sword of Yitian" in the weight loss field, but also the "Dragon-Slaying Saber" that the entire pharmaceutical world has been seeking for years as a treatment for Alzheimer's disease.
This is simply a case of an overwhelmingly lucky situation that even web novels wouldn't dare to write.
Subsequently, Novo Nordisk, in a state of excitement, made a very aggressive decision.
On December 16, 2020, Novo Nordisk officially announced the launch of the pivotal Phase III clinical trial program for oral semaglutide (14mg formulation) in the treatment of early Alzheimer's disease, namely the EVOKE and EVOKE+ clinical studies, which have now been declared a failure.
At the time, this decision was considered extremely bold, as skipping Phase II clinical trials and moving directly to Phase III is a very rare move in the AD field.
The final result proved that it was a disaster.
Although Novo Nordisk has never disclosed the individual cost of the aforementioned clinical study, according toThe standard cost model for Phase III clinical trials of Alzheimer's disease in the global pharmaceutical industry indicates that the actual cost of these two clinical studies, with a combined enrollment of over 3,600 patients, should far exceed 1 billion US dollars.
The final results of these two clinical trials not only largely ruled out the possibility of GLP-1 drugs treating Alzheimer's disease but also more harshly rejected some prevailing views in the industry regarding Alzheimer's disease.
Novo Nordisk's announced information shows that semaglutideIt did improve some biomarkers associated with metabolism and inflammation, but the therapeutic effect on Alzheimer's disease was almost zero.
This suggests that the correlation between the metabolic axis and Alzheimer's disease is far weaker than previously thought by the industry, and may even be entirely unrelated.
The pooled analysis data released by Novo Nordisk in 2020, which claimed a "53% reduction in risk," had a denominator of 15,000 people, while the numerator was only 47 cases (32 cases + 15 cases), which is very likely to be just an accidental and random data fluctuation.
If Novo Nordisk's failure can be attributed to somewhat overly casual factors, Johnson & Johnson’s recent failed clinical trial, which was considered by the industry as one of the "most rigorously designed and scientifically well-founded" studies for treating Alzheimer’s disease at its inception, presents a stark contrast.
After the "Amyloid Hypothesis" in Alzheimer's disease was disproven by multiple failed clinical trials, Johnson & Johnson set its sights on Tau protein.
There is indeed a lot of anatomical and imaging evidence in the industry showing that,AmyloidThe amount of deposition is not correlated with the progression of Alzheimer's disease. On the contrary, the amount and location of Tau protein deposition exhibit a strong linear relationship with cognitive decline.
Johnson & Johnson has launched a monoclonal antibody, Posdinemab, which is...Mainly targeting extracellular Tau proteins, attempting to "ambush and eliminate" the pathological proteins during their transfer from one neuron to others. The underlying logic is: by blocking the transmission pathway, the condition can be localized, preventing a complete collapse of the brain's neural system.
In the selection of patients, Johnson & Johnson also adopted a highly differentiated strategy, based on the assumption that:If the patient is in the early stage, with little Tau protein, the drug efficacy may not be obvious; if the patient is in the late stage, the Tau protein has already completed sufficient transmission, and the significance of "blocking" is minimal.
Thus, in the middle stage of disease progression, that isPatients with Tau protein that has just started to spread but has not yet reached an overwhelming level have become the target of Johnson & Johnson.
In order to achieve the above patient screening, Johnson & Johnson also specificallyDeveloped a proprietary blood-based biomarker, even performed PET scans on patients to determine eligibility for enrollment.
Even based on such rigorous logical assumptions, the outcome still ended in failure.
By the end of November 2025, Johnson & Johnson announced that based on the interim analysis results, Posdinemab did not achieve statistical significance in slowing the clinical progression of Alzheimer's disease.
This result is not only the failure of a single clinical trial, but also points to a pessimistic conclusion: regarding the pathogenesis of Alzheimer's disease, after the amyloid hypothesis has been largely disproven, the Tau protein hypothesis is likely incorrect as well.
Johnson & Johnson's failure this time is not due to careless clinical trial design or poor execution, but rather because humanity's current understanding of the pathophysiological mechanisms of Alzheimer’s disease may still have fundamental flaws.
The most despairing thing is that all the roads tried so far may have been wrong.
Currently, there are more than 6 million new cases of Alzheimer's disease globally each year, with over 50 million existing patients. Treating this "extremely challenging" condition still requires significantly more effort.
Johnson & Johnson stated that it will continue to develop drugs for Alzheimer's disease and continue to advance, includingIncluding JNJ-2056Other Tau Protein Projects.
Click "PharmSnap" below”, follow more exciting content
Disclaimer
The push rules of WeChat Official Accounts have changed again. If you don't tap"Views"Or not set to"Star Mark", we might just dissipate in the vast ocean of text~ Click here, don't miss out on PharmaDJ's latest updates!??